此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

视网膜脱离结果研究 (REDOS)

2026年11月4日 更新者:CHU de Quebec-Universite Laval

孔源性视网膜脱离伴或不伴巩膜扣带 (REDOS) 试验:一项析因随机对照试验

Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade.

Methods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results.

Discussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.

研究概览

研究类型

介入性

注册 (估计的)

560

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Quebec
      • Québec、Quebec、加拿大、G1S4L8
        • 招聘中
        • Hôpital du Saint-Sacrement, CHU de Québec - Université Laval
        • 接触:
          • Julie Mauger

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥18 years
  • Diagnosis of rhegmatogenous retinal detachment

Exclusion Criteria, retinal detachment with:

  • Proliferative vitreoretinopathy (PVR) grade ≥C2
  • Chronic RRD with duration >3 months
  • Proliferative diabetic retinopathy with tractional retinal detachment (RD)
  • Macular holes
  • Epiretinal membrane grade 3 or 4
  • Traumatic RD
  • Giant retinal tears
  • Retinal dialysis
  • Foveoschisis
  • Wet age-related macular degeneration
  • Endophthalmitis
  • Acute retinal necrosis
  • Coats disease
  • Retinopathy of prematurity
  • Retinoschisis
  • Retinal colobomas
  • Prior glaucoma surgery or strabismus surgery (favoring PPV only)
  • Superior RD extent less than 3 clock hours (favoring PPV only)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
有源比较器:平坦部玻璃体切除术+六氟化硫气体填塞

Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.

其他名称:
  • PPV

At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.

其他名称:
  • 六氟化硫
实验性的:巩膜带扣玻璃体切除术+六氟化硫气体填塞

At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.

其他名称:
  • 六氟化硫

In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.

其他名称:
  • PPV-SB
实验性的:睫状体平坦部玻璃体切除术+全氟丙烷气体填塞

Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.

其他名称:
  • PPV

At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.

其他名称:
  • C3F8
实验性的:带巩膜扣带+全氟丙烷气体填塞的睫状体平坦部玻璃体切除术

In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.

其他名称:
  • PPV-SB

At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.

其他名称:
  • C3F8

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Single surgery anatomic success
大体时间:Until final 1 year follow-up

Freedom from reoperation for recurrent RRD

Until final 1 year follow-up

次要结果测量

结果测量
大体时间
最佳矫正视力
大体时间:1年
1年
RD 复发的时间
大体时间:直到最后 1 年的随访
直到最后 1 年的随访
并发症的严重程度和数量
大体时间:直到最后 1 年的随访
直到最后 1 年的随访
生活质量问卷
大体时间:2周、8-10周、6个月、12个月
2周、8-10周、6个月、12个月
针孔视力
大体时间:8-10周,6个月
8-10周,6个月

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ali Dirani, MD MSc MPH、CHU de Québec - Université Laval
  • 首席研究员:Mélanie Hébert, MD MSc、CHU de Québec - Université Laval

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年9月26日

初级完成 (估计的)

2027年7月1日

研究完成 (估计的)

2028年7月1日

研究注册日期

首次提交

2023年5月8日

首先提交符合 QC 标准的

2023年5月16日

首次发布 (实际的)

2023年5月18日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The full protocol will be published in the journal Trials. The final trial dataset could be made available to other research teams upon reasonable request and after evaluation of the request by the trial team. The shared dataset will be coded and will not include any identifying patient data.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅